### Draft Guidance on Netupitant; Palonosetron Hydrochloride

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

<table>
<thead>
<tr>
<th>Active Ingredient:</th>
<th>Netupitant; Palonosetron hydrochloride</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage Form; Route:</td>
<td>Capsule; oral</td>
</tr>
<tr>
<td>Recommended Studies:</td>
<td>Two in vivo studies</td>
</tr>
</tbody>
</table>

1. **Type of study:** Fasting  
   **Design:** Single-dose, two-way crossover or parallel group  
   **Strength:** 300 mg; EQ 0.5 mg Base  
   **Subjects:** Healthy males and nonpregnant females, general population  
   **Additional comments:**  
   a. Female subjects should not be pregnant or lactating, and if applicable, should practice abstention or contraception during the study.  
   b. Ensure adequate washout periods between treatments in the crossover studies due to their long terminal elimination half-life. A parallel study design may also be used due to the drug’s long half-life. For long half-life drug products with low intra-subject variability in distribution and clearance, an AUC truncated to 72 hours may be used in place of AUC$_{0-t}$ or AUC$_{0-\infty}$. For either a crossover or a parallel study, sample collection time should be adequate to ensure completion of gastrointestinal transit of the drug product and absorption of the drug substance. Collect sufficient blood samples in the bioequivalence studies to adequately characterize the peak concentration (C$_{max}$) and time to reach peak concentration (T$_{max}$).

2. **Type of study:** Fed  
   **Design:** Single-dose, two-way crossover in vivo  
   **Strength:** 300 mg; EQ 0.5 mg Base  
   **Subjects:** Healthy males and nonpregnant females, general population  
   **Additional comments:** Same as comments above

**Analytes to measure (in appropriate biological fluid):** Netupitant and palonosetron in plasma

**Bioequivalence based on (90% CI):** Netupitant and palonosetron

**Waiver request of in vivo testing:** Not applicable

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods Web site, available to the public at the following location: [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and

---

*Recommended Sept. 2015*
reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).